2016-01-07

Camurus's initial public offering a success

On Thursday December 3, 2015, Camurus started its first day of trading on Nasdaq Stockholm. The share price increased considerably during the first day and Camurus is now the largest company in the biotechnology sector on Nasdaq Stockholm

The price of the Camurus share was set at SEK 57, but at closing time the share was noted at SEK 65,5, an increase of no less than 15,7 percent. The upturn meant that the market capitalization of Camurus was close to SEK 2,5 million at the end of the day. Today (January 2016) the market capitalization is about SEK 2,8 million.

Sandberg Development will remain the largest shareholder in Camurus and will hold appr. 54 percent of the total number of shares in the company.

Latest news

2018-12-07

Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence

Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead p…

Read more

2018-11-22

Camurus receives EU approval for Buvidal®

Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. Buvidal® is the first…

Read more

2018-10-26

AF Bostäder has installed SWATAB's filter system

AF Bostäder in Lund will open two new laundry rooms at Vildanden, a student housing, where the students can wash wit…

Read more

2018-10-26

Camurus Interim Report January-September 2018

“Following the positive CHMP opinion for Buvidal®, we have ramped up our commercial activities and are ready for lau…

Read more

2018-07-20

Solo Rescue to spin-off from GRANULDISK

Sandberg Development has decided to spin-off and concentrate the business within the subsidiary GRANULDISK’s product…

Read more